Zynteglo and Skysona combine for 16 patient starts since approvals last year
Bluebird bio’s gene therapy Zynteglo, which was approved by the FDA to treat patients with transfusion-dependent thalassemia last August, hasn’t had many takers.
Bluebird said Tuesday in its second-quarter results that 11 patients have started Zynteglo since its launch, though the company said there have been no denials from payers, and prior authorization takes about two weeks.
The company reported a total of $6.8 million in revenue for the quarter, attributable to Zynteglo, which costs $2.8 million per treatment, and Skysona, a gene therapy approved last September to treat active cerebral adrenoleukodystrophy (CALD). Its stock $BLUE was up about 10% in trading on Tuesday afternoon.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.